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Abstract
The immunodeﬁciency, centromeric region instability,a nd facial anomalies syndrome (ICF) is the only disease known to
result from am utated DNA methyltransferase gene, namely, DNMT3B.C haracteristic of this recessive disease are decreases
in serum immunoglobulins despite the presence of Bc ells and, in the juxtacentromeric heterochromatin of chromosomes 1
and 16, chromatin decondensation, distinctive rearrangements, and satellite DNA hypomethylation. Although DNMT3B is
involved in speciﬁc associations with histone deacetylases, HP1, other DNMTs, chromatin remodelling proteins, condensin,
and other nuclear proteins, it is probably the partial loss of catalytic activity that is responsible for the disease. In microarray
experiments and real-time RT-PCR assays,w eo bserved signiﬁcant differences in RNA levels from ICF vs.c ontrol
lymphoblasts for pro- and anti-apoptotic genes ( BCL2L10, CASP1,a nd PTPN13); nitrous oxide, carbon monoxide, NF-k B,
and TNFa signalling pathway genes ( PRKCH, GUCY1A3, GUCY1B3, MAPK13; HMOX1,a nd MAP4K4); and
transcription control genes ( NR2F2 and SMARCA2). This gene dysregulation could contribute to the immunodeﬁciencya nd
other symptoms of ICF and might result from the limited losses of DNA methylation although ICF-related promoter
hypomethylation was not observed for six of the above examined genes. We propose that hypomethylation of satellite 2a t1 qh
and 16qh might provoke this dysregulation gene expression by trans effects from altered sequestration of transcription factors,
changes in nuclear architecture, or expression of noncoding RNAs.
Keywords: Immunodeﬁciency,c onstitutive heterochromatin, cancer,D NA methyltransferases,c hromosomal rearrangements,
DNA demethylation
ICF: Introduction to the syndrome
Thei mmunodeﬁciency,c entromeric regioni nstability
andf aciala nomalies syndrome (ICF)i sarare recessive
diseasec haracterized by targeted chromosome
breakage [1]. Them ajorityo fc ases of ICFt hath ave
been studiedi nvolve mutationsi none of thet hree main
DNAmethyltransferasegenes,DNMT3B[2–4].These
DNMT3B mutationsa re usuallym issense changes
within thec odingp ortion of theg ene[ 5–8]. This is the
only known geneticd isease in humans involving
mutationsi no ne of theg enes encoding an enzyme that
methylates cytosiner esiduesi nD NA.
ICFi sa ni mmunodeﬁciency diseaset hat hasb een
described in fewert han5 0p atientsw orld-wide[ 9,10]
sinceitwas ﬁrstdescribedin thelate 1970s[11,12].Itis
diagnosedb yimmunoglobulindeﬁciencythat isusually
seen in thep resenceo fn ormalB -a nd T-cell counts,
characteristicchromosomalabnormalitiesinthevicinity
ofthecentromereofcertainchromosomes,and,usually,
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Autoimmunity,J une2 008; 41(4): 253–271also faciala nomalies.T he immunodeﬁciency of ICF
patientsislargelyresponsiblefortheirfrequentmortality
inearlyc hildhood.The chromosomalabnormalities are
instabilityt hat is almost exclusively foundi nt he
juxtacentromeric heterochromatin( qh)r egions of
chromosomes1and1 6, ands ometimes 9( Figure 1).
In addition,a ll studiedI CF tissuesa nd cell cultures
displayh ypomethylation of satellite2DNA( Sat2)i n
1qhand16qh,therelatedsatellite3DNA(Sat3)in9qh,
and, form ales,i nY qh satelliteD NA [13,14].
In this review,w ew ill brieﬂy describe the ICF
phenotype, then atureo fk nown ICF-associated
mutations in DNMT3B ,a nd why it is likelyt hatI CF
is actually due to loss of the enzymatic activity of
DNMT3B andn ot to alterationsi ni ts speciﬁc
protein–protein interactions. The relationships of
DNA hypomethylation andc hromosome abnormal-
ities in the ICF syndrome and in cancer will also be
discussed. Lastly, the questiono fa bnormal gene
expression in ICFl ymphoblastoid cells will be
addressed in some detail with previously unreported
data from an expression microarray analysis anda n
inferred model of how ICF-related DNA hypomethy-
lation leads to the disease.
ICF-linked DNMT3B mutations
DNMT3Bo verview
ICFp atientsw ith DNMT3B mutations[ 2,4,10]a re
sometimesr eferredt oa se xhibitingI CF type 1d isease
[7].Thesepatientsareusuallycompoundheterozygotes
withvariousmutationswithinthegene[5,6,10].Inmice,
Dnmt3b is an essentialg enef or normal development
[15].I nsertional inactivation of Dnmt3b or Dnmt1
resultsi np renatald eath soon afteri mplantation[ 15].
In murinek nock-outso ft he thirdm ajor DNMT gene,
Dnmt3a,d eath is observed severalw eeks afterb irth.
In humans,i fI CF-causing mutationsi n DNMT3B did
notl eave residual activity,e mbryonic lethalityw ould
probablyresult.ThisresidualDNAmethylationactivity
hasb eeno bserved in vitro [16] andi sc onsistentw ith
resultsf rom in vivo mousem odels[ 17]. Therefore, we
predictt hath omozygousn ull DNMT3B mutations
wouldl eadt os pontaneous abortions.
Human DNMT3B and murine Dnmt3b( 94%
identity)a nd humanD NMT3A andm urineD nmt3a
(98% identity [18])h avep redominant rolesi n de novo
methylationo fD NA (methylation of CpGd yads that
were symmetrically unmethylated)[ 19]. Thesea re
enzymesareespeciallyimportantduringembryogenesis
andg ametogenesis [20,21]althoughtheira ctivityi sn ot
limitedt ot heses tagesi nd evelopment. DNMT3B and
DNMT3A aren ot redundanti nt erms of function [22],
as validatedb yt he ﬁnding that DNMT3B mutations
sufﬁce to causeI CF.T hey differ in expression patterns
during murined evelopment [23] although they can
interact ands timulate each other’sa ctivity[ 24]. They
have some distinct preferencesf or sequencesﬂ anking
theC pG dinucleotide andf or chromosomalr egions
[19,20,25].T heya lsod ifferi nr elativea ctivity in vitro
Figure 1. Hypomethylated DNA in constitutiveh eterochromatin in ICF.C artoon illustrating the constitutive heterochromatin regions that
displayI CF-speciﬁch ypomethylation and chromosome abnormalities.D ark gray box, juxtacentromeric (pericentromeric) heterochromatin;
white box, centromere.
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[26]. Complicatinga nalysis of thef unctiono f
DNMT3B/ Dnmt3b and DNMT3A/ Dnmt3 ag enep ro-
ductsa re then umerousi soformst hat they encode,
whichs how non-coordinate expression [22]. For
example, oneo ft he DNMT3B isoforms is missing
conservedm otifsi nt he catalyticd omainb ut evidence
suggests that it is stillb iologically important[ 27].
DNMT3Bm utations in ICF patients( ICF type 1)
ICF type 1i st he only formo fI CF whose genetic
etiology is known.I ti nvolves biallelic DNMT3B
mutations [10]. Unless otherwise noted, ICF will
denotetype1inthisreview.TheICF-linkedDNMT3B
mutationsareoftenmissensemutationsandareusually
found in the parto ft he gene encoding the catalytically
activeC-terminalportionoftheprotein,namely,oneof
ten motifs conserved among all cytosine-C5 methyl-
transferases [1,2,4,5,10,15,28].
The involvement of DNAh ypomethylation in the
phenotype of ICF is supported at the cytogenetic level.
ICF-speciﬁc rearrangements in mitogen-treated lym-
phocytes from patientsa re the samei nf requency,
spectrumandchromosomalspeciﬁcityasthosethatwe
found in an ormalp ro-B lymphoblastoid cell line
treatedw itht he DNA methylationi nhibitors5 -
azacytidine or 5-azadeoxycytidine [29,30]. The invar-
ianthypomethylationofcertainportionsofthegenome
in ICF cells and tissues, most notably Sat2 [1,13], is
also consistent with ICF being due to DNA methyl-
ation deﬁciency.
Noncatalytic functions of DNMT3B
DNMT3B hasrepressoractivitythatisindependentof
its DNAm ethyltransferase activity [31]. Accordingly,
DNMT3Bh as many speciﬁc protein-interaction
domains, whicha re usually outside the C-terminal
catalytic domain [32–34].T he speciﬁc binding
partners of DNMT3Bi nclude theo ther DNA
methyltransferasesD NMT1a nd DNMT3A, histone
deacetylases HDAC1a nd HDAC2, HP1 a ,t he
chromatin remodelling protein hSNF2H, the conden-
sing complex hCAP-C/hCAP-E, andt he mitotic
chromosome-associatedK IF4A [33–35]. DNMT3B
is subject to sumoylation [32], which involves addition
of as mall SUMO protein to al ysine residue in a
particular protein motif [36]. Sumoylation can affect
protein–proteini nteractions, protein activity and
proteinl ocalization[ 37]. Thes umoylationa nd
PWWPchromatintargetingdomainsintheN-terminal
half of DNMT3Bp robably are responsible for intra-
nuclear andh eterochromatin targetingo ft he enzyme,
respectively [32,38,39], which can occur in ac ell type-
speciﬁc manner [31]. Satellite DNA methylation does
not appear to be necessaryf or targeting of Dnmt3b to
heterochromatin in murine embryonal stem cells [31]
but Sat2 hypomethylation might be involved in the
exaggerated targeting of 1qha nd 16qht oi ntranuclear
bodies[ 40], as will be described below.
The only ICF-associated missense mutation out-
sidet he catalyticC -terminalh alfo fD NMT3B
(S282P)i sw ithin the PWWPd omaina nd was
found in both DNMT3Ba lleles in two related ICF
patients [28]. The analogous mutation in mouse cells
resulted in thel osso fd etectablet argetingt o
constitutive heterochromatin in interphase and meta-
phase [38]. This redistributionc ould explain the
hypomethylation of Sat2 in the juxtacentromeric
constitutive heterochromatino ft hese twoI CF
patients [28]d espite the persistence of methyltrans-
ferasea ctivity in vitro [38].
The functional importanceofthe non-catalyticroles
of DNMT3B/Dnmt3b was illustrated by studies of
differentiation of rat pheochromocytoma cells (PC12)
into neuronal cells. Induction of differentiation in
PC12 cellsm ediated by nerve growth factor was
inhibited by antisenseo rs mall interfering RNA
(siRNA) for Dnmt3b [41]. This inhibition couldb e
largely reversed by transfectionw ithaplasmid
encoding Dnmt3b, either wild-type or mutated in the
C-terminalcatalyticdomainsoastoinactivatecatalytic
activity,b ut not by mutantsm issingt he central ATRX
domainorN-terminalPWWPdomain.Oneofthenon-
catalytic,neuronaldifferentiation-relatedtargetsofthe
Dnmt3bistheT-cadherinpromoterwhoseactivitywas
repressed by Dnmt3b irrespectiveo ft his promoter’s
methylation status [42].
Generally,m utant DNMT3B proteins from ICF
cellsa re still able to engage in normal protein–protein
interactions [34]. One exception is an ICF mutation
that alterst he amino-terminal region of DNMT3B’s
catalytic domain, and, in am ouse mutant interferes
with ac atalysis-enhancing interaction of Dnmt3a and
Dnmt3b [17]. The other exceptionsa re two mutations
in the Ct erminal half of DNMT3B that did not
appreciablyr educe catalytic activity but did greatly
reduce its interaction with Dnmt3L [43]( see below).
These exceptionsf urther implicatel osso fD NA
methylation, and not some other biological activity of
DNMT3B, as the upstream molecular defect causing
the ICF syndrome.
Stimulation of DNMT3Bc atalytic activity by interaction
with DNMT3L
There is as peciﬁc DNMT3L interaction domain
located in the C-terminus of Dnmt3b/DNMT3B
[44]. DNMT3L is an on-catalyticp rotein neededf or
establishment of DNA methylation patterns in the
germline, includingm aternal methylation imprinting
and normal levels of methylation of satellite DNA
sequences [20]. DNMT3L stimulates the catalytic
activity of Dnmt3a and Dnmt3b methyltransferases
[45]. This mayi nvolve contact of DNMT3Ba nd
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organization of DNMT3B, just as DNTM3L reor-
ganizes theo ligomerizationo ft he DNMT3A2
isoformo fD NMT3A [46]. Importantly, two ICF-
associated DNMT3B mutations (A766P and R840Q)
that result in proteins with approximately wild-type
basal methylation activity exhibit decreased associ-
ationw ithD NMT3La nd as trongd ecreasei n
stimulation by DNMT3L [43]. These resultsi mpli-
cate interaction of DNMT3B with DNMT3L as
critical for normalD NA methylation that is protective
against the ICF phenotype.
ICF type 2: Not associated withD NMT3Bm utations
About40%ofICFpatientshavenomutationsinexons
of DNMT3B [7,10]. There might be mutations in the
promoter or other transcription control elementso r
mutations affecting splicing or polyadenylation. How-
ever, for several of these ICF patientswithout detected
DNMT3B mutations, the most common isoformo f
DNMT3B RNAwas still observed[ 7], and for the one
patient examined in two putative promoter regions of
DNMT3B ,n om utations were found [8]. Moreover,
mRNA froma nI CF patientw ithout detected
mutations in DNMT3B was examined by RT-PCR
withprimersorampliconsizesspeciﬁcforseveralofthe
DNMT3B RNA splice variants 3B4, 3B3, and3 B1
[47].N oe videncef or pathogenic alterations in
DNMT3B splicing patterns was uncovered.
ICFp atientsw ithout DNMT3B coding region
mutations seem to be derived from ad ifferent subtype
ofthedisease.Lymphocytesorﬁbroblastsfromallnine
patientsi nt his category displayed hypomethylation in
satellite a (centromeric; Figure 1) DNA while all ﬁve
examined patientsw ho had mutations in DNMT3B
did not havet he pericentromeric DNA hypomethyla-
tion extending into the centromere [7]. ICF patients
without mutations in DNMT3B exhibit the same Sat2
hypomethylation and chromosomal anomalies at 1qh
and 16qh in mitogen-stimulatedc ells seen in patients
with DNMT3B mutations [8,13,14,48].
Variability of clinical aspects
Immunodeﬁciency
The immunodeﬁciencyd isplayed by ICFp atients,
despitet he presence of Bc ells, results in severe
recurrent infectionso ften seen in early childhood [49–
51]. ICF immunodeﬁciencyi sv ariable ranging from
agammaglobulinemia to am ild reduction in immune
response [10,52]. In one study,2 7o ut of 44 patients
presented with agammaglobulinemia althought hey
had Bc ells in the peripheral blood[ 10]. All but oneo f
ther est hadh ypogammaglobulinemia, onew ith
selective IgA, two with IgM, and one with IgG2
subclassdeﬁciency.NormalpercentagesofTcellswere
observed in 36 of 38 ICF patients, the expected
stimulation of T-cell proliferation in 25 of 28 tested
patients, andC D4
þ cellsw ere decreased in only ﬁve of
38 patients.
Other symptoms
The dysmorphic facial features of ICF are variable,
usually mild [50,53], and frequent[ 10]. The typical
facial features areab road ﬂatn asal bridge,
hypertelorism (very widely spaced eyes), epicanthic
folds andl ow-set ears. Lessf requentb ut still often
associated with the syndrome are micrognathia (small
jaw) andm acroglossia (protrusion or enlargemento f
the tongue) [6,28,53–56].F ailuret ot hrive and low
birth weight are observed in about half of the patients
[10]. Mental retardation and neurologic defects have
been seeni na bout one-thirdo ft he patients
[10,50,53,57]. Otherc ongenitala bnormalitiesi n
ICF are highly variable being observed in one or a
few patients. These include bipartite nipples [57], skin
pigment changes [12,57,58], scleral telangiectasias
[57], inguinal hernia andc left palate [10].
How similara re the Dnmt3b mutant mice
to humanI CF patients?
TwomissenseICFmutationswereintroducedintoboth
Dnmt3b allelesi nm iceb yh omologousl oxP/cre-driven
recombination[ 17]. Both affect thec atalytic domain in
theC -terminalp ortionofthep rotein [2,4]. ThreeI CF-
relatedt ransgenicmouse linesw ereg enerated thatwere
homozygous foro ne or theo ther of these Dnmt3b
mutationso rt he compound heterozygote.
The missense Dnmt3b mutant mice went to term
unlike the equivalent Dnmt3b homozygousn ullm ice,
which died between 13.5 and 16.5 day post coitum
[17]. Most of the missense mutant mice died within
1d ay of birth althoughs ome survived through to
adulthood. Those that survived displayed low birth
weight andf acial anomalies (shorter nose and wider
nasalb ridge) reminiscent of theI CF syndrome.
Although their immunes ystem was abnormal, the
identiﬁed abnormalitywasintheT-celllineage.One or
two daysa fter birth, theyh ad reduced amounts of
thymocytes, apparently due to apoptosis, and high
levels of fragmented nuclei in the thymus.I nc ontrast,
the immunodeﬁciencyo fI CF patients only infre-
quently involves decreased levelso fTcells [1,10] but
alwaysischaracterizedbyreducedlevelsofoneormore
of the types of immunoglobulins. Normal levels of B
cellsw ere observed in these mice as is usually the case
for ICF patients.
As describeda bove, only ICF Type 2p atients (who
do not display DNMT3B mutations) exhibit hypo-
methylation of centromeric satellite DNA (Figure 1).
The Dnmt3b missense mutant mice displayed hypo-
methylation of murine minor satellite DNA,w hich is
centromeric,aswellasofmajorsatelliteDNA,whichis
juxtacentromeric[ 17]. No mention was made in this
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in an earlier reportf rom this group, aneuploidy,
polyploidy andn umerous breaksa nd fusions in
chromosomes were observedi nm urine embryonic
ﬁbroblasts with double knockout of Dnmt3b [59]. This
is veryd ifferent from the chromosomal abnormalities
inICF,whichdonotincludeaneuploidyorpolyploidy,
and are localized almost exclusively to the juxtacen-
tromerich eterochromatin of only af ew chromosomes,
those with long regions of Sat2 [1,14] (see below).
Therefore,t he DNAh ypomethylation and chromoso-
mal abnormalities in mice with Dnmt3b mutations or
derived cell cultures is more extensive (including
centromeric as well as juxtacentromericD NA)t han in
the DNMT3B -mutant ICF syndrome in humans, even
when comparing the same DNMT3B mutations, and
the nature of the immune dysfunction is different.
These differences between species in ad isease that
most prominently affects satellite DNA-rich hetero-
chromatin are not surprising. Mice do not haveS at2-
orSat3-likesequencesintheirgenome,wheresomuch
of the ICF DNA hypomethylation is concentrated
[60].Moreover,murinechromosomesareacrocentric,
rather than mostly metacentric, as forh uman
chromosomes, including those harbouring most of
the Sat2 or Sat3 DNA. At the end of this review,w e
will discuss our hypothesis thatS at2 hypomethylation
plays an indirect causative role in ICF.
ICF DNA hypomethylation and relationship
to cancer
ICF DNA hypomethylation
Juxtacentromeric satellite DNA in normal somatic
tissuesi sg enerally highly methylated[ 61]. The
hypomethylation of satellite DNA sequences in ICF
cells at 1qh, 9qh, 16qh, and Yqh appearst ob ea n
invariantcharacteristic ofICFasdetected bySouthern
blot analysis with CpG methylation-sensitive restric-
tione ndonucleasesa nd by immunocytochemistry
with anti-m
5 Ca ntibodies [13,14,60]. By bisulﬁte-
basedg enomic sequencing,S at2 in ICF lymphoblas-
toid cell lines (LCLs) and ﬁbroblast cell strains was
found to have abouto ne-third the methylation of
analogous controls [62]. The controls had an average
of 69% methylation of CpG dinucleotides. By hairpin
genomics equencing,w er ecentlys howed that normal
somatic tissues havea verages of 81, 12 and7 %
symmetrically methylated, symmetrically unmethy-
lated and hemimethylated CpG dyads, respectively
(C. Shao, M. Lacey,a nd M. Ehrlich, submitted).
InadditiontoSat2andSat3,satelliteDNA at Yqh is
hypomethylated in ICF cells [13,60]. Another class of
ICF-hypomethylated heterochromatic sequences is in
facultative heterochromatin, the inactive Xc hromo-
some of females( X i)[ 60,63,64]. Hypomethylation of
examinedCpGislandsontheXchromosomehasbeen
found in some, but nota ll, ICF patientso nt heir X i
[1,51,63]. ICF-related Yqh andX i hypomethylation
is unlikely to be of biological signiﬁcanceb ecause no
gender-speciﬁc differences in symptomsh aveb een
reported for this disease, and, for X i genes, the
hypomethylation is often inconsistent from patient to
patient. Analysis of methylation of imprinted genes in
ICF has not revealed any gene region with consistent
hypomethylationa mong examinedp atients [52].
Therefore, these gene regions tooa re unlikely to
contribute to the ICF phenotype.
By HPLC analysis of DNA digests, we demon-
strated that the hypomethylation of the genome in ICF
involves only ar athers mall percentage of the 5-
methylcytosine residues, namely 7% hypomethylation
inbrainDNA[14].We conﬁrmedthatthemethylation
abnormality of ICF is conﬁned to as mall fraction of
the genome by two-dimensional electrophoresis of
restriction digests of DNA from fourI CF vs. four
control LCLs [65]. Only 13 of the approximately one
thousand spotsd isplayedc onsistentI CF-speciﬁc
differences,a nd all but one of these was derived
from NBL2 andD 4Z4 tandemr epeats. These repeats
are dissimilar from each other and from Sat2 orSat3 in
sequence, G þ Cc ontent, andc hromosomal location
(acrocentric,s ubtelomeric, or juxtacentromeric)
despitet heir common ICF hypomethylation [65–
67].T hat only al imiteda mount of consistent DNA
demethylation is associated with ICF,a nd mostly in
DNA repeats, should be takeni nto account in models
of howD NMT3B mutation gives rise to the disease.
Sperm DNA hypomethylation: Similarities
with ICF and cancer DNA hypomethylation
Normal human spermd isplaysh ypomethylation in
juxtacentromericS at2 andS at3, subtelomeric D4Z4
arrays,andacrocentricchromosomalNBL2sequences
as do ICF cellsa nd somatic tissues [13,61,62,65,66].
Unlike ICF Type 1, but like Type 2a nd av eryh igh
percentage ofcancers,spermalsodisplayshypomethy-
lation of centromeric Sata sequences [68,69]. Sat2,
D4Z4, and NBL2 exhibit less methylation in puriﬁed
normalspermthandoICFcells[14,67](unpub.data).
In mice,j uxtacentromeric( major satellite)a nd
centromeric (minor satellite) repeats are hypomethy-
lated in botho ocytes ands perm [70]. Imprinted genes
and high-copy interspersed repeats are differentially
methylated in spermv s. oocyte DNA [71,72].
Accordingly,t here are differences in the prevalence of
transcripts for Dnmt3b, Dnmt3a, Dnmt1, Dnmt1s
(a Dnmt1 splice variant), andD nmt3L during the
course of gametogenesis in the male vs. the female
germline [21].
Given the involvement of DNMT3Bi nt he ICF
syndromea nd ICF-linked hypomethylation of the
aboved escribedt andemr epeats,i ti sc lear that this
enzyme is necessaryd uring development for normal
methylation of these sequences in human somatic
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in these repeats in ICF somatic cells, whicha re higher
than those of sperm, might be due to either DNMT3A
and/or residualD NMT3B activity.T he restructuring
of chromatin composition during spermatogenesis
[73] might inhibit access of satellite DNA and other
large tandem repeats to DNMT3B or facilitate access
to as yet uncertain DNA demethylation machinery
[74,75] so as to explain the low levels of methylation of
these sequences in sperm.
Frequent increases in methylation of someD NA
sequences andd ecreases in methylation of othersa re
seen in aw ide varietyo fc ancers[ 61].T here is often
more hypomethylationt hanh ypermethylationo f
DNA during carcinogenesis, leading to an et decrease
in theg enomic 5-methylcytosine content[ 76].
Although the exact methylation changes between
different cancerso ft he same type are not the same,
therea re cancer type-speciﬁc differences in the
frequency of hypermethylation or hypomethylation
of certain genomics equences. These opposite types of
DNAm ethylation changesa ppear to be mostly
independent of one another, althought heym ay arise
because of as imilara bnormality leading to long-
lasting epigenetic instability in cancers[ 77]. Evidence
of hypermethylation of some DNA sequences in ICF
has been sought but has notb een found. Therefore,
unlike cancers,I CF DNAh as exhibitedo nly
hypomethylation.
ICF chromosomal rearrangements
and relationship to rearrangements in cancer
ICF-type chromosomalr earrangements
Diagnosiso fI CF usuallyi nvolvesc ytogenetic detection
of chromosome rearrangements targeted to Sat2-rich
1qha nd 16qh [9,53] (Figure1 ). Standardm etaphase
analysis of mitogen-stimulated lymphocytes from
peripheralb loodo fI CF patients revealsp redominantly
chromosomeb reaks, whole-armd eletions, multi-
branched chromosomesw ithu pt ot en arms of Chr1
and/or Chr16, and, less frequently,t ranslocations, and
isochromosomes (usuallycontainingtwo1 qa rms fused
in thej uxtacentromericr egion) [1,53].F requently,
therei sd econdensationi n1qh or 16qh in ICFL CLso r
stimulated lymphocytes [14,78]. This decondensation
is probably relatedt ot he shifti nr eplication timing of
Sat2 from mostly G2/M andv eryl ate in Sp hase and
towardsm oreo ft he Sat2 replicatingi nSphase,
includingi ni ntermediates tageso fSphase[ 62].
The decondensationo f1 qh and1 6qh in ICF
lymphoblastoid cells is likely to be critical to the ICF-
typerearrangementsintheseregions.Indirectevidence
for more frequents omatic paring of 1qh and1 6qh in
ICF lymphocytes than in control lymphocytes was
reported[79].InICFLCLs, multiradialscomposedof
arms of both Chr1 and Chr16 had been shown to be
favoured over homologous associations[ 14]. We had
proposed that those multiradials represent unresolved
Holliday junctions. In collaborationw ith David
Gisselsson, we analyzed chromosome dynamicsa t
mitosis and the frequency of genomic imbalances in
ICFLCLs[80].Consistentwithour model,theresults
suggest that illegitimate recombination of heterochro-
matic sequences at interphase due to increased 1qh
and 16qh associations in ICF LCLs leads to severe
perturbations at mitosis.
DNMT3B co-localizes throughoutm itosis with
components of thec hromosomec ondensation
machinery( hSNF2H,K IF4A,h CAP-C,a nd hCAP-
G) in HeLa cells [35]. These proteins were associated
with Sat2 and rDNA in interphase as determined by
chromatin immunoprecipitation of ac ontrol LCL,
althought he extento fa ssociation was not quantitated.
In ICF LCLs,o ne of these proteins, hSNF2H, was
tested for its association with DNMT3B andf ound to
still coprecipitate with the mutant DNMT3B [34].
Nonetheless, these proteins and HP1, whichi sh ighly
concentrated in G2-phase ICF lymphoblasts in an
anomalous giant nuclear body containing Sat2 DNA
[40], might have ar ole in the ICF-speciﬁc chromoso-
mal abnormalities at 1qh and1 6qh.
BecauseaDNMT inhibitorc an gived istinctive ICF-
like rearrangements in ap ro-B-celll ine, including
multiradialc hromosomes [29,30]a nd canc ause
decondensation of constitutive heterochromatin[ 81],
it is likely that ICF-linked Sat2 hypomethylation
contributes to the ICF-associated 1qh and 16qh
abnormalities. Others tudies of humanl ymphocytes
andB -celll ines also supportarelationship of DNA
hypomethylation pers e andI CF-typec hromosomal
abnormalities[ 82,83] as does thea ssociation of
juxtacentromeric DNAd emethylationa nd chromo-
some rearrangementsi nc ancer( seeb elow). None-
theless,h ypomethylationo fs atellite DNA in
constitutive heterochromatini nI CF cellsd oesn ot
sufﬁcetopromoterearrangementsbecausethelong9qh
region( Figure 1) with itsS at3h ypomethylation in ICF
only veryi nfrequently displays rearrangements in
mitogen-stimulated lymphocytes from ICFp atients
[9,14].T he even longer Yqhr egion( Figure 1),w hich
also is hypomethylated in ICFc ells [13],h as notb een
reportedtobesusceptibletorearrangementinICFcells.
Moreover, the cell type and cell growth conditions
inﬂuence the association of rearrangements with Sat2
hypomethylation. WhileS at2-hypomethylated chor-
ionic villus cultures havea ni ncreased frequencyo f
these rearrangements, they are only seen in av eryl ow
percentageofthemetaphasesinculturesatlowpassage
numbers [84]. That frequencyi ncreases dramatically
at higher passages. In ICF cells, the frequencyo f
chromosomalr earrangementsa t1 qh and1 6qh
depends on cell growth [1,9]. In vitro mitogen
stimulation of lymphocytesg reatly increasest he
development of these aberrant chromosomes inde-
pendent of its role in inducing cycling. Am uch higher
M. Ehrlich et al. 258frequency of juxtacentromeric (pericentromeric)
rearrangements of Chr1 andC hr16 per metaphase is
seen 72 or 96ha fter mitogen stimulation of ICF
lymphocytest hana t4 8h,a lthough the frequent
abnormal decondensation of 1qha nd 16qh can be
observed in metaphases at 48h[ 12,53,85].T he
rearrangements observedi nm itogen-stimulated ICF
lymphocytes andi nu ntreated ICF LCLs may occur
in vivo,b ut at av eryl ow rate, as deduced from studies
of micronucleus formation in unstimulatedb one
marrow andl ymphocytes fromI CF patients
[53,58,86]. The viability of ICF patientsa nd cell-type
speciﬁcity of the disease, mostly an immunodeﬁciency
disease, indicates that ag eneralized breakdown in 1qh
and 16qh chromatin stability is not manifest through-
out the tissues of ICF patients.
Relationship of chromosomalr earrangements
in ICF to similarr earrangements in cancer
ICF-type chromosome rearrangements have been seen
incancers[87].Chr1/Chr16multiradialchromosomes,
whicha re expected to be very short-liveds tructures
[14],a nd decondensation in Sat2-rich1 qh have been
observed in multiple myeloma and hepatocellular
carcinomas [88,89]. In urothelial carcinomas and
glioblastomas, therei se videncef or an associationo f
DNAh ypomethylation with juxtacentromeric chromo-
somalr earrangements[ 90,91].U nbalancedC hr1a nd
Chr16j uxtacentromeric rearrangementsa re overrepre-
sentedinawidevarietyofcancers[92].Theunbalanced
nature of theser earrangements couldf ostert umorigen-
esis by resultingc hanges in copy number of oncogenes
or tumors uppressorg enes [61].S tudies of mice with
geneticallye ngineeredD NA hypomethylationd ue to
hypomorphicm utations in Dnmt1 providef urther
evidence that DNAh ypomethylation canp redispose
to chromosome rearrangements[ 93].
Canceri ncidence in ICF patients
Studiesf romD NA-hypomethylated mice give
evidence of ac ausal relationship between genomic
hypomethylation and cancer, but only certain types of
cancer [77,94]. Although ICF had notb een associated
with cancer,f ewer than 50 patients( mostly children)
haveb een identiﬁed. Their usually very short average
lifespan would preclude detectiono facancer
predisposition that was not very high andd id not
result in tumorsr atherq uickly. However, recently an
ICF patient of 7y earsw as reported to haveH odgkin
lymphoma [95], and previously an unrelatedI CF
patient was describeda sh aving an adrenocortical
adenoma[ 8]. Then ormalo rh eightened DNA
damager esponse observed in ICF lymphocytes [96]
might helpe xplain why tumorsh aven ot been found
more frequently in ICF patients comparedt op atients
with shortl ife expectancies due to several otherr are
chromosomal instabilitys yndromes[ 97].
Altered gene expression in ICF lymphoblastoid
cells
Overview of ICF microarraye xpression analyses
Because ICF patients can havev eryl arge decreases in
speciﬁc serum immunoglobulins despite the usually
normal levels of Bc ells [5,10], transcriptional
dysregulation in Bc ells or both Ba nd Tc ellsi sl ikely
to be the predominant cause of their immunodeﬁ-
ciency. We showed that ICF LCLs havep lentiful
surface IgM and normal IgM RNA levels [5] despite
extremely low levels of serum IgM. Therefore, the
immuned efect in ICF occursa tastep prior to class
switching. It was suggested thatp eripheral blood-
derivedBcellsandBLCLsinICFpatientsmaydisplay
analteredexpressionpatternonlyasresultofbeingless
mature than their normal counterparts [98]. However,
the absence of detectable IgM in serum from 12 out of
45 patients[ 10]i ndicates an intrinsic defect in Bc ells
in ICF patients. Moreover, the differences in the
expression patterns of ICF LCLs compared to control
LCLsdescribedbelowargueformorethanjustalossof
maturity of Bc ells. Fore xample, we found signiﬁcant
differences in RNA levels in ICF vs. control LCLs for
some genes expressed only in mature Bc ells, others
knowntobeexpressedmainlyintheT-celllineage,and
yet othersw ith no known or expected relationship to
lymphogenesis.
We didt wo microarraye xpressione xperimentso n
ICFa nd controlL CLs. They involved B-cell linesf rom
ICF patients with known and diverse DNMT3B
mutationsa nd from controls,i ncluding phenotypically
normal parentso ft he patients.I nt he ﬁrsts tudy,t otal
RNA( cRNA) from ICFL CLsd erived from ﬁve
differentp atientsa nd ﬁvec ontrol LCLswere examined
on oligonucleotide arrays for , 8400 genes( Affyarray
HuGene FL,A ffymetrix) [5]. Thef oldc hange( FC)
wasd etermined, namely,t he relative RNAs ignall evels
inICFv s. controlo rc ontrolvs.I CF.A bout0.3% ofthe
genesw eref ound to be up-o rd own-regulateda ta
signiﬁcancel evel (two-sample t -test) of P , 0.05 and
FC . 2.0o r P , 0.01 andF C . 1.5. In thes econd
experiment,e ight ICF ands even control LCLs,
includingﬁ ve andt wo from theﬁ rsts tudy,r espectively,
were analyzed on oligonucleotides arraysr epresenting
, 33,000genes(AffyarrayU133AandBarrays).Inthis
analysis, , 1% of theg enes showeda nF C . 2( up-o r
down-regulation) and P , 0.01 forI CF-speciﬁc differ-
encesinRNAlevels.Dysregulationinvolved120probe-
sets that were down-regulated and2 29 up-regulated.
The summaryd ataf or 20 of these genes of interest
from the second experiment are shown in Tables Ia nd
II. Nine were also found to be dysregulated in the ﬁrst
microarray experiment and eight were similarlyu p- or
down-regulated in two different probe sets in the
second experiment. By quantitative real-time RT-PCR
(qRT-PCR), we veriﬁed that the following RNAsw ere
overexpressed in eight ICF LCLs compared to eight
ICF,a nI mmunodeﬁciencyD NMT3B-DeﬁciencyS yndrome 259T
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ICF,a nI mmunodeﬁciencyD NMT3B-DeﬁciencyS yndrome 261control LCLs:t he transcriptionf actor NR2F2
( COUP- TFII); SMARCA2 ( BRM), encoding a SNF2
subunit of ac hromatin remodelling complex; PRKCH
and PTPN13 ( FAP-1 ), whichr egulate apoptosis;
GUCY1B3 and GUCY1A3,w hiche ncode the two
subunitso fasoluble guanylate cyclase, and CD44 and
CKLF,w hicha re implicated in the laters tages of B-
cell development. Although the terms up- or down-
regulation are used, ac aveat is that differences in post-
transcriptional processing are sometimes responsible
for changes in the steady-state levels of RNA,t he
parameter monitored in these studies.
Twelveg enes with signiﬁcant differences from the
microarray data between ICF and control LCLs were
then tested by RT-PCR. Only one of these did not
exhibit RT-PCR resultsc oncordant with the micro-
array results (data not shown). In addition, oneg ene,
RGS1 ,w hichd isplayed ICF-speciﬁc changes in its
RNA levelsonlyintheﬁrstmicroarrayexperiment, did
not show signiﬁcant differences in RNAl evels in ICF
vs.controlLCLsbyqRT-PCR(datanotshown).Some
otherg enes also displayed signiﬁcant differences in
RNA levels between ICFand control LCLs only in the
ﬁrst experiment [5]. However, the microarrayf or the
ﬁrst experiment was smaller, the gene annotation was
muchl ess thorough, andt he probe sets were different
from those in the second experiment (usually 20
oligonucleotidesp er set in the ﬁrst experiment and1 1
in the second). These factorsa nd the absence of some
oftheprobesetsor theapparentlypoorerhybridization
of others can explain why some of the genes that
appearedt ob es igniﬁcantly dysregulated in ICF LCLs
comparedtocontrolLCLsintheﬁrstarrayexperiment
were not seen as dysregulated in the second.
In view of the extreme scarcity of ICF patients and
their median age of 8y earsa td eath [10], we examined
Epstein Barrv irus-transformedB -cell lines rather
than lymphocytes. The activation associated with this
transformation might hide some in vivo defects in B-
cell activation in ICF patients and only as ubset of B
cells will be transformed. Nonetheless, we found
muchc onsistencyi nL CLs from eight unrelated
patientsa nd new insightsi nto transcriptional regu-
lation of the immune system.
Genesw ith lymphocyte functionst hat had alteredR NA
levels in ICF LCLs
The most dramatic differencei nR NA levelsi nI CF vs.
controlL CLs was seen for IGHG3 (Table I). This was
expected based upon results givenr esultsf rom the
patient sera and surface immunoglobulin expression
[5]. The second largest difference in RNA levelsi n
diseasec ompared to control LCLs in Table Io rI Iw as
observed for MAP4K4, which has been implicated in
antigen-mediated T-cell activation [99] but not in B-
cell function.T hisu biquitously expressedk inase
participates in the JNK/TNF-a and p53s ignalling
pathways andc an be controlleda tt he levelo f
transcription[ 100–102]. The maximum microarray
signalf or MAP4K4 in the controlL CLs in the second
microarray experiment was4 6w hile,w itht he
exception of one LCL (ICF K), the ICF LCLs had
muchh ighers ignals (371, 2893, 295, 291, 1856, 348
and 1060).M AP4K4 seems to haveab road role in
fostering cell migration[ 103]. Anotherg enew hose
RNA was upregulated in ICF vs. control LCLs was
NT5E,w hich was found to be expressed mostly in B
cells, rathert han Tc ells, and usually only after isotype
switching [104].
CD27,whichplaysakeyroleinT-cellmemoryandin
the stimulation of Bc ells to produce immunoglobulins
[105], hadl ower mRNA levels in ICF LCLs relative to
control LCLs (Table I). This is consistent with ICF
immuned ysfunction. The ability of peripheralb lood-
derived Bc ells (CD19
þ )t oe xpressc ell-surface CD27
after stimulation [98]makes the down-regulation of its
RNA in ICF lymphoblastoid cells unlikely to be
causally involved in ICF immunodeﬁciency. While
CD40, CD44, CKLF and ITGB2( CD18) mRNAs
weresigniﬁcantlyupregulatedinICFvs.controlLCLs,
their positive functions in lymphogenesis [106–112]
maket hem unlikely candidates for active playersi nt he
immunodeﬁciencyo fI CF patients.S omeg ene
candidates for interfering with later stages of B-cell
differentiation or activation did not display signiﬁcant
differencesinRNAlevelsinICFvs.controlLCLsinthe
microarray analysis, namely, BTK, PRDM1, PAX5,
IRF4, BCL6 , XBP1, BACH2 and MAPBPIP .
Cell death or growth arrest genes that had altered RNA
levels in ICFL CLs
Genesi nvolved in cell deatho ra rrest of the cell cycle
mayb ei mportant contributors to thei mmune
dysfunctiono fI CF patients. CASP1 , BCL2L10,
PTPN13, HMOX1 , MAPK13 and PRKCH ,w hich
displayed ICF-speciﬁc differences in their RNA levels,
might be involved in abnormal regulation of apoptosis
or cell cycle arrest in lymphoid cells in ICF patients
(TablesIandII).However,majordecreasesinnumbers
of lymphocytes are notu sually found to be associated
withICF.LowlevelsofTcellsarepresentinonlyhalfof
ICF patientsand thelevels ofBc ells areevenless likely
to be lower than normal in ICF patients and are never
undetectable[ 1,9]. Nonetheless, too much cell death
induced by B-cell activation just in the laters tages of
B-celldevelopmentcouldleadtothelossofplasmacells
and decreased serum immunoglobulin without com-
promising total levels of Bc ells.
CASP1( TableI )i sacytokinei nvolvedi navariety of
inﬂammatoryp rocesses,i ncludingt he proteolytic
maturation of thei nactive precursoro ft he inﬂamma-
tory cytokines interleukin-1 (IL1)a nd IL18 [113]. It is
pro-apoptotic in various cell typesa nd mayb e
associated with IgAd eﬁciency andi ncreased apoptosis
M. Ehrlich et al. 262in Bc ells [114]. Therefore, theo bservedi ncreased
levels of CASP1R NA in ICFv s. controlL CLsa re
consistent with theh eighteneds usceptibilityo fI CF
lymphoid cellst oa poptosis [80,86,115,116].O ver-
expression of CASP1R NA in ICFc ells coulda lso
perturbN F-k Bs ignallingp athwaysi mpacting
expression of otherg enes (seebelow).U nderexpression
of RNAf or thea nti-apoptoticH MOX1 stress protein
ando verexpressiono fM APK13a nd PRKCHR NA in
ICFv s. controlL CLs( TableI I) mighta lsoc ontribute
to pro-apoptotict endencieso fI CF lymphoid cells.
TherewassigniﬁcantlymoreBCL2L10RNAinICF
LCLs compared to controlL CLs (Table II). This
widely expressedm embero ft he BCL2 family has a
polypeptide structure compatible with both pro-a nd
anti-apoptotic effects depending on the cell type and
conditions [117]. It appearst ob eanegative regulator
of cell death in humang lioma cells provoking them to
exit from the cell cycle [118]. While ICF LCLs were
hypersensitive to g radiationc omparedt oc ontrols, we
demonstrated that this was mostly due to irreversible
growth inhibition, secondarily to non-apoptotic cell
death,a nd thirdly to apoptosis [96]. All three of these
typesofresponsestoirradiationweresigniﬁcantlymore
frequentf or ICF cellst han for controlc ells despitet he
functional cell cycle checkpoints in ICF cells.
Givent hatt he main anti-proliferative response of
ICFL CLst o g radiationw as nota poptosis,i ti s
noteworthy that PTPN13,ag enew itha nti-apoptotic
effectsw as overexpressed in mRNA from ICFv s.
control LCLs (Table II). Thisp rotein tyrosine
phosphatasei nteracts with diversep roteinsi ncluding
thec elld eath FASp rotein [119]. Thei nteraction with
FASd ecreases thee xporto fF AS to thec ell surface and
therebyo pposes theF AS pro-apoptotic activity.
PTPN13 mays uppressp ro-apoptotic signalling also
througha nother interactivep artner,aneurotrophin
receptor [120]. However, as forB CL2L10,a no pposite
pro-apoptoticr olef or PTPN13 hasa lsob eenr eported
[121], in this case,i nvolving dephosphorylationo ft he
insulinreceptorsubstrate-1.Northernblotting revealed
very strong signalsf or PTPN13 RNAi np lacenta and
testes (botht issues with considerable DNAh ypo-
methylation[ 61,122]),a sw ella sf or kidney;m oderate
signalsi nl unga nd ovary;w eaks ignals in heart, brain
andp ancreas; anda lmostn od etectables ignali n
leukocytes[ 123].W itht he much more sensitiveR T-
PCRa ssay,P TPN13R NA wasd etectedi nTc ells and
wasf ound to be decreasedu ponI L-2a ctivation
although it wasm orea bundanti nC D45RO
þ memory
Tc ells than in CD45RA þ naiveTcells[ 124].
Overlapping upregulationo fR NA for kinases
and NO or CO signalp athway members
Them icroarrayr esults suggestt hato verlapping signal
transduction pathways mayb ec ritical fort he immune
dysfunctiono fthe ICFsyndrome(Tables Iand II).One
of these involves thea forementionedC ASP1 and
PTPN13,w hose RNAs were upregulatedi nI CF vs.
controlL CLs. In addition to itsc atalytic function,
CASP1has anon-catalytic role,asactivatorinBcells of
NF- k Bandp38MAPK,theMAPKfamilythatincludes
MAPK13[125].AnincreaseinNF- k Bsignallingisalso
predictedf romi ncreased PTPN13 RNA, becauset he
corresponding proteinp hosphatase hasa so ne of its
substrates I k B a ,w hich inhibits NF-k B[ 126].
In addition,N F-k Bu pregulates PTPN13 transcription
[119]a nd playsacriticalr olei nl ymphocyted evelop-
ment andf unction[ 127,128].
Anothers ignallingp athway with ICF-speciﬁc
differences in RNA for several of its membersi st he
carbonm onoxide (CO)p athway (Table II). HMOX1,
which displayed ICF-speciﬁc decreases in RNA levels,
catabolizes heme and therebyr eleases gaseous CO,
which is responsible for its anti-apoptotic effects
[129]. This pathwaya lsoi nvolvesd ownstream
activation of NF-k B, which,i nt urn, by promoter
interactions, activates transcriptionf rom as ubset of
NF-k B-dependent anti-apoptotic genes [129–131].
Among the diverse effects of CO signalling,i ts eems to
be am odulator of autoimmunity [129].
Anotherl inkt ot he NF-k Bs ignalp athways among
the ICF-overexpressedR NAsi nvolves the above-
mentioned proteink inase Cf amily member,
PRKCH. This calcium-independent, serine-a nd
threonine-speciﬁc enzyme is activated by diacylgly-
cerolt op hosphorylate awide range of cellular proteins
and therebyi nﬂuence many aspects of physiology
[132–135].U nlikelym ost protein kinase Ci soforms,
transcriptiono f PRKCH is highly tissue speciﬁc. Its
expression primarily,b ut not exclusively, in epithelial
tissues is probably due to an enhancer, as ilencer and
trans-actingf actors[ 136].I ns kin,P RKCH is
associated with terminal differentiation of keratino-
cytes. Genetic polymorphismsi n PRKCH are impli-
cated in increasingt he risk of rheumatoid arthritis and
cerebral infarction [135,137]. Overexpression of
PRKCH mayp lay ar ole in tumor progression through
downstream ERK and ELK effectors [132]. PRKCH
RNAwasoverexpressed4-to14-foldinICFvs.control
LCLsasseeninbothmicroarrayexperimentsandqRT-
PCR( Table II). It is implicated as ap ro-apoptotic
protein in early B-cell development [138]. PRKCH
RNA was reportedt ob ei nduced upon lymphocyte
activation but was present at much lower levelsi nB
cellsthaninTcells,whether restingoractivated[137].
Amongtheprocessessubjecttoitsregulation,PRKCH
helps controlt he activation of NF-k Bu pon lipopoly-
saccharide induction of primaryr at astrocytes [133].
PRKCH activity can result in the production of nitric
oxide (NO), another important signalling gas, via the
inducible nitric oxide synthetase gene( iNOS)[ 134].
Thew idespreads ignallingm oleculeN Oi s, in turn,
relatedt oG UCY1A3 andG UCY1B3,w hose RNAs
were upregulatedi nI CF compared to controlL CLsa s
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(Table II). GUCY1A3a nd GUCY1B3a re thet wo
subunits ofthesoluble guanylatecyclase(sGC),aheme
proteinthatisamajorsensorforNO,therebyregulating
diversep hysiologicalp rocesses,[ 129].P roliferation of
Th elper( Th)1cellsi sc ontrolledb yN Ol evels[ 139].
Although GUCY1A3 and GUCY1B3 arev eryc lose
together on 4q32.1,t heym ay notb er egulated in af ully
coordinate manner [140], as is consistent with ourd ata
(TableII).TheirheterodimericproductsGC isstrongly
stimulated by NO andw eaklys timulatedb yC O.
TheN Oa nd CO pathways intersect in variousw aysa t
thep rotein level, includingt hat decreasedH OX1i n
ICFv s. controlL CLsc ould lead to less HOX1-
mediatedd egradation of theh emep rosthetic
group necessaryf or theG UCY1B3 subunito fs GC
[141]. Anotherp athway intersectiono ft he genesi n
Tables Ia nd II is that MAPK13 hasaprominentr olea s
ad ownstreame nzymei nt he sGCs ignallingp athway
[129].I CF-relatedo verexpression of RNAs for
MAPK13 andt he twos GC subunits is consistent
with theiri nterrelatedf unctioning in cell growth arrest.
Some of the genes in Tables Ia nd II that exhibited
ICF-related changes in RNA levels in the Bl ympho-
blastoid cellsa re much more closely associated with T
cells than with Bc ells. This might reﬂect coordinate
dysregulation in the B-cell and T-cell lineages. For
those genes, it might be that only dysregulation in T
cells is relevant to the diseaseo rt hat the role of these
genes in Bc ells is insufﬁciently appreciated. Alter-
natively,t hese changesm ight contribute to the
pathology of ICF because of inappropriate expression
of T-cell speciﬁc genes in the B-cell lineage.
Dysregulation of genes that may help explain non-immune
symptomso fI CF
While the signiﬁcantly altered RNA levelsf or some
proteins in ICF vs. control LCLs, such as the CNN
actin-binding protein,m ight have no biological
consequences, othersm ay be af actor in the non-
immunes ymptoms of ICF.A lthough we examined
RNA only in BL CLs,a bnormal RNA levels in the
lymphoid cell lineage might be found in other lineages
too and altered regulation in lymphocytes can some-
times mirror more physiologically important dysregu-
lation in av eryd ifferent tissue [142]. Overexpression
of PTPN13 RNA in ICF LCLs (Table II) might
pertaint on eurologicalﬁ ndingsi nI CF patients
because high levels of PTPN13 in fetal brain and its
ability to bind to the neurotrophinr eceptor implicate
this protein in controlling neuronal celld eath
[120,143]. One of the neurological abnormalities in
ICF is seizures, which was reported in three of 45
patients[ 10]. SLC1A1, an euronalp rotein involved in
transporting glutamatet hati sp rotectivea gainst
seizures and neuronal death[ 144], was signiﬁcantly
underexpressed at the RNA leveli nI CF LCLs relative
to controlL CLs (TableI I). In addition, the observed
BCL2L10R NA dysregulation may be involved in
ICF-related neurological disturbances because
BCL2L10m RNA increases appreciably from av ery
low level during in vitro differentiation of rat astrocytes
[145].Moreover,GUCY1B3 andiNOSareassociated
with each other in certain areas of the hippocampus in
mice[ 146]a nd CASP1 overexpression has been
linkedt oc ognitive impairment with aging [147].
Upregulation of PRKCH( TableI I) maye xplain a
perplexingﬁ nding reported in one studyo ft wo
unrelated ICF patients,b oth of whom displayed
bipartiten ipples [57].P RKCH is implicated in
upregulation of many epithelial tissues, includingt he
mammaryglandi nrats[148].Theseassociationsmight
accountf or theo ccasionals peciﬁc ﬁnding of bipartite
nipplesi nI CF patients.
ICF-associated upregulation of RNAf or thec hro-
matinr emodelling proteinS MARCA2m ight impact
1qha nd 16qh decondensation.S MARCA2( BRM) is
an importantm odulator of chromatina ssembly[ 149].
Itcoulda lsohavedisparatedownstreame ffects through
itsi mpacto nt ranscriptionalr egulation, DNAr epair
andh omologousr ecombination.
Lack of detectable methylation changes in the promoter
regions of examined ICF-upregulatedg enes
We recently examined methylation of ﬁve genes with
qRT-PCR-conﬁrmed ICF-associated upregulation of
their RNA,n amely, GUCY1A3, PTPN13, NR2F2,
SMARCA2 and CKLF (Tables Ia nd II). Their 5 0 gene
region (for GUCY1A3)o ru pstream regions (fort he
otherg enes) were assayed for methylation in ICF and
control LCLs as well as in several normal tissues by
combined bisulﬁter estrictiona nalysis( COBRA).
COBRA allows quantitationo fD NA methylation
levels at restriction endonuclease sites in ag iven DNA
sequence that is ampliﬁed by PCR[ 150]. Genes with
up-regulationo fR NA were chosen because of the
frequent association of DNAh ypomethylation in
promotersw itht ranscription [151]. By COBRA, we
saw no consistent ICF-speciﬁc differences in DNA
methylation in the examined regions despite their
ICF-related increases in the levels of the correspond-
ing mRNAs (Figure 2a nd data not shown). This was
similart oo ur previous ﬁnding for GUCY1B3 in ICF
cells[ 5]. Almost allo ft he immediate upstream regions
were constitutively unmethylated. There were various
amounts of partialm ethylationi nt heir further
upstream sequences but no correlations between
methylationa nd RNA levels amongi ndividual
LCLs. Therefore,t he differential mRNA levelsf or
these genes in ICF vs. control LCLs could notb e
explained by differences in methylation in or near their
promoters. Ac aveat in this analysis is that only the
top gene in an ICF-activated transcription pathway
might have ICF-speciﬁc promoter hypomethylation.
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mutations to the ICF phenotype
Methylation analysis of various genes [51,52,63,64]
(Figure 2), and whole-genomer estriction analysis
[65] have revealed consistent hypomethylation only in
tandem DNA repeats (including satellite DNA)a nd
X-linked sequences in X i .H owever, unconventional
genes,w hoseb road biological inﬂuence has been
appreciated only recently (especially microRNAa nd
anti-sense RNA genes) [152], were not speciﬁcally
examined. While ac ritical genet hat is hypomethylated
speciﬁcally in ICF cells mayh aveb een missed, we
favour ad ifferent explanation for the connection of
selective DNA hypomethylation to the ICF syndrome.
We propose that the pathogenicity of DNMT3B
mutations in ICF patients is due to the hypomethyla-
tion of constitutive heterochromatin.T hiss ame
explanation can be applied to patientsw ith ICF type
2, who have no detected DNMT3B mutations but do
exhibit the characteristic hypomethylation of juxta-
centromeric satellite DNA [7].Because no genderbias
has beenr eported for ICF,o ur proposal for the
involvement of satellite DNA is limited to the long
juxtacentromeric heterochromatin butn ot Yqh
(Figure 1) nor the facultativeh eterochromatin of X i.
We favour the involvement of Sat2-containing1 qh
and1 6qho verS at3-containing9 qh (Figure1 )
because of the more frequent cytogenetic abnormal-
ities in the formerr egions.
Evidence is mounting that constitutive heterochro-
matin is biologically important andn ot just an inert
ﬁller in the genome,a sm any previously thought.
In ﬁssion yeast and drosophila, transcription of non-
coding RNA is important for the establishment of
constitutive heterochromatin [153–155]; these organ-
isms have littleo rn om ethylation of their DNA [16].
Some,b ut not all, of various tested normal or cancer
samples andh alf of ICF LCLs that we analyzed for
Sat2 RNA were positive by RT-PCR (which included
controls for DNA contamination) andb ya ssays for
RNA polymerasee ngagement [156]. However, these
signals were very low andw ed id not see the large
increase in Sat2 transcripts upon heat shock[ 156] that
is found for 9qh Sat3 transcripts [157].
Besides constitutive heterochromatin yielding non-
coding transcripts that might affect expression of
protein-coding genes, its intranuclearl ocation may
help organize chromatin throughout the nucleus so as
to modulateg ene expression in trans [85]. Evidence
fort hisp henomenonh as been reported in the
lymphoid lineage [158,159]. The intranucleard istri-
butiono fc entromeres in lymphoid cells is distinct for
the cell type and stage of differentiation and involves
genesa ssociated with lymphogenesis [160]. The
importance of the spatial location of chromatini n
the nucleus is illustratedb yt he ﬁnding that much gene
expression occursi nt ranscriptionf actories that are
speciﬁc for different functional groups of genes [161].
Figure 2. Analysiso fDNAmethylationupstreamofPTPN13.RepresentativeCOBRAanalysisforDNAmethylationofagenethathadRNA
upregulatedi nI CF vs. control LCLs. DNA samples had been modiﬁed with bisulﬁte and ampliﬁed by PCR with primers at the indicated
positions as previously described [5]. The PCR products could be cleavedb yT aqI or BstUI only if they had been methylated at the CpG
dinucleotidei nt he indicated sites in genomic DNA; the pre-TaqI site, CCGA, would be converted to aT aqI site, TCGA, upon bisulﬁte
treatmentandPCRifitwasCm5CGAingenomicDNA.(A)Diagramofthe5 0 PTPNregionshowingthetranscriptionstartsite(TSS)[123]at
Chr487,734,909(hg18,UCSCdatabase),the5 0 CpGisland( 2 701to2 150),andPCRprimers;positionsaregivenrelativetotheTSS.(B)and
(C),electrophoresisgelsstainedwithethidiumbromideandvisualizedforﬂuorescentbandsfromthePCRproducts( 2 628to2 119and2 1250
to 2 940) digested with BstUI or Taq I. PBMC, peripheral blood mononuclear cells; ICF LCLs are described in the legend to Table I, with the
addition of another control LCL (AG14832, Coriell Institute). Sizes are giveni nb pf or the expected and obtained restriction products.
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DNA mighti nﬂuence thed istributiono ft hese
heterochromatic regions in the nucleus during certain
stages in lymphogenesis or lymphocyte activation and
therebya ffect expressionf rom geneso no ther
chromosomes.
Recently,o ne dramatic changei np ositioning of
hypomethylated constitutive heterochromatin speciﬁ-
cally in ICF lymphoblasts and lymphocytes has been
described. It is the formation of ag iant promyelocytic
leukemia (PML) type nuclear bodyt hat correlated
with undercondensed1 qh or 16qh, but not 9qh, in a
large percentage of ICFG 2n uclei[ 39,40]. Allt hree
isoforms of HP1a sw ell as SP100, SUMO-1,
transcriptionf actorsC BP and DAXX,t he DNA
helicase BLM, and the SWI-SNF remodelling protein
ATRX co-localize in this single nuclear body. Much
smaller PML-type bodies containing these proteins
are observedi nG 2-phase nuclei of normal cells but
the association of 1qh Sat2 DNA with these normal
bodiesi sl ess frequentt han for the giant PML nuclear
body in ICF lymphocytes and LCLs. This abnormal
concentrationo fs atellite DNA heterochromatin and
nuclear proteins in ICF G2-stage lymphoid cellsh as
been proposed to be linked to undercondensation and
chromosomal abnormalities at 1qh and 16qh[ 40].
However, it might also reﬂect an abnormal distri-
butiono fc hromatinp roteins in interphase that could
inﬂuencee xpressiono fg enes elsewherei nt he
genome.
There are more andm ore examples of transcription
controlp roteins that bind selectively to constitutive
heterochromatin [162–168]. Furthermore, there is
evidence that the binding of at least some of these
transcriptionf actorst ot he highlyr epetitive DNA of
constitutive heterochromatin sequesterst hese pro-
teins in ar eversible manner so as to modulate
expression of sets of genes [5,168–172]. Methylation
of satellite DNA can dramatically alter binding of
certain transcription controlp roteins to DNA, in
general [173] or constitutive heterochromatin [174],
in particular. Therefore, pathogenic dysregulation of a
subset of genes in ICF might be due to altered
transcriptionf actorb inding to satelliteD NA in
response to its disease-related hypomethylation. This
would be an ew type of DNAm ethylation control of
gene expression in trans mediatedb yc hromatin acting
as ad ynamic reservoir fors torage andp ossibly
deliveryo ft ranscriptionm odulatoryp roteins, which
in the case of ICF,m ight explain the life-threatening
immunodeﬁciency.
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